Bio-Techne joins Cell and Gene Therapy Catapult PAT consortium

By The Science Advisory Board staff writers

June 8, 2021 -- Bio-Techne is joining the Cell and Gene Therapy Catapult process analytical technology (PAT) consortium, which includes over 20 pharmaceutical companies, technology providers, therapy developers, and charities.

The consortium will assess the application and combination of multiple technologies for process analytics within the cell and gene therapy industry. Its first initiative is to unite companies and organizations from multiple industries to develop cell and gene therapy specific process analytical technologies.

These technologies will enable monitoring and control during the manufacturing process, including improving batch yields and lowering manufacturing costs. Consortium members will collaborate and share research findings to integrate and combine cell and gene therapy PAT into their respective offerings.

Bio-Techne posts revenue gains in Q3
Bio-Techne reported strong growth in revenues for its third quarter, thanks largely to sales in its protein analysis business.
908 Devices, Bio-Techne partner on protein characterization workflow
908 Devices and Bio-Techne are collaborating to develop an extended workflow solution for protein characterization.
Bio-Techne releases new in situ hybridization assay
Bio-Techne has released DNAscope Assay, a new in situ hybridization assay kit.
Bio-Techne launches Abby automated western system
Bio-Techne announced that its brand ProteinSimple has released Abby, its next-generation chemiluminescence system that automates traditional western blotting.
Bio-Techne launches new product for organoid, stem cell cultures
Bio-Techne has released its new Cultrex UltiMatrix Reduced Growth Factor Basement Membrane Extract (RGF BME) to support organoid and pluripotent stem...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter